Clinical Trial

Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus Disease

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 5, 2025 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-center, open-label clinical trial designed to evaluate the early bactericidal activity (EBA) of sitafloxacin against Mycobacterium abscessus disease. Patients with Mycobacterium abscessus disease were enrolled and treated with sitafloxacin monotherapy for 14 days. Colony forming units (CFU) and time to positivity (TTP) in sputum cultures were analyzed and compared. By assessing the impact of sitafloxacin monotherapy on the bacteria in the sputum of patients with Mycobacterium abscessus disease, the early bactericidal activity of sitafloxacin was evaluated, providing a basis for the selection of new drugs for the treatment of Mycobacterium abscessus disease.
Trial Details
NCT Number NCT06809413
Lead Sponsor Beijing Chest Hospital
Conditions Fluoroquinolone, Mycobacterium
Enrollment 12 participants
Start Date 2025-01-28
Primary Completion 2025-05-31 (estimated)
Study Completion 2025-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-05